Xtandi vs Imbruvica
A side-by-side look at two oncology medications advertised on TV. Informational only — not medical advice.
| US Xtandi | US Imbruvica | |
|---|---|---|
| Generic name | enzalutamide | ibrutinib |
| Drug class | Androgen Receptor Inhibitor | BTK Inhibitor |
| Treats | Prostate cancer | Chronic lymphocytic leukemia and other blood cancers |
| Category | Oncology | Oncology |
| Manufacturer | Astellas/Pfizer | AbbVie/Janssen |
| Year approved | 2012 | 2013 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | $90M | — |
| Common side effects | Fatigue, Hot flashes, High blood pressure, Falls | Bleeding and bruising, Irregular heartbeat (atrial fibrillation), High blood pressure, Infections |
Frequently asked questions
Is Xtandi or Imbruvica better?
Neither is universally "better." Xtandi (enzalutamide) and Imbruvica (ibrutinib) are both used for oncology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Xtandi and Imbruvica?
Xtandi is a Androgen Receptor Inhibitor made by Astellas/Pfizer, while Imbruvica is a BTK Inhibitor made by AbbVie/Janssen. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Xtandi has the larger estimated TV advertising budget of the two.